Michael C. Milone, MD, PhD
Associate Professor of Pathology and Laboratory Medicine at the
Hospital of the University of Pennsylvania
Associate Director, Toxicology Laboratory
Perelman School of Medicine at the University of Pennsylvania
Associate Vice Chair for Faculty Development & Academic Affairs
Contact InformationHospital of the University of Pennsylvania
Department of Pathology and Laboratory Medicine
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Tel: 215-662-6575
Fax: 215-662-7529
Email: milone@pennmedicine.upenn.edu
Specialty Division
Laboratory Medicine, Cancer and Immunobiology
Research Expertise
Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease. Active research projects in my laboratory include:
1) Developing chimeric antigen receptors (CARs) for adoptive immunotherapy of cancer with enhanced function and improved safety.
2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.
3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.
Clinical Expertise
Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis
Itmat Expertise
My laboratory is focused upon developing methods to use the immune system to treat cancer. Active research includes 1) exploring the mechanical properties of artificial adhesion substrates used in T cell culture and their influence on T cell biology, 2) development of artificial antigen receptors and signaling systems for control of T cell specificity
Graduate Groups
Cell and Molecular Biology
Education
B.S (Chemical Biology), Stevens Institute of Technology, 1993
Ph.D (Experimental Pathology/ Immunology), UMDNJ - Graduate School of Biomedical Sciences, 1999
M.D. (Medical Doctor), UMDNJ- New Jersey Medical School, 1999
Specialty Certification
Clinical Pathology, American Board of Pathology, 2002
Postgraduate Training
Internship, Internal Medicine, Hospital of the University of Pennsylvania, 1999-2000
Resident, Clinical Pathology, Hospital of the University of Pennsylvania, 2000-2002
Chief Resident, Division of Laboratory Medicine, Hospital of the University of Pennsylvania, 2001-2002
Clinical Fellowship, Blood Banking and Transfusion Medicine, Hospital of the University of Pennsylvania, 2002-2003
Postdoctoral. Research Fellow, Translational Research Program, Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, 2003-2007
Clinical Fellow, Clinical Chemistry and Laboratory Toxicology, Hospital of the University of Pennsylvania, 2004-2007
Awards and Honors
Stanley S. Bergen Award for Academic Excellence, UMDNJ, 1996
Stanely S. Bergen Medal of Excellence, UMDNJ, 1999
Faculty Organization Award, UMDNJ-New Jersey Medical School, 1999
The Peter C. Nowell Teaching Award, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 2011
Top Ten Clinical Research Achievement Award, Clinical Research Forum, 2017
Top 20 Clinical Research Papers for 2019, Clinical Research Forum, 2019
Though Leader Award, Agilent Technologies, 2020
Memberships and Professional Organizations
American Society of Clinical Pharmacology and Therapeutics, 2007 - 2010
American Association of Clinical Chemistry, 2007 - Present
College of American Pathologists, 2008 - Present
American Society of Hematology, 2008 - Present
Academy of Clinical Laboratory Physicians and Scientists, 2008 - 2015
American Association of Immunologists, 2009 - Present
American Society of Gene and Cell Therapy, 2009 - Present
International Association of Therapeutic Drug Monitoring and Clinical Toxicology, 2009 - Present
American Society of Clinical Pathology, 2015 - Present
National Institute for innovation in Manufacturing Biopharmaceuticals (NIIMBL), 2017 - Present
Web Links
Selected Publications
Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells
Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, Chen L, Wilkins K, Baker DJ, Rommel PC, Jarocha D, Gohil M, Zhang Q, Milone MC, Fraietta JA, Davis M, Young RM, June CH., Proc Natl Acad Sci U S A 122(): e2427216122, 2025, PMID:40324075
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis
Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, Milone MC., Cancer Chemother Pharmacol 95(): 32, 2025, PMID:39932505
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I. J., Gabrielli, G., Nasta, S. D., Porazzi, P., Landsburg, D. J., Gerson, J. N., Carter, J., Barta, S. K., Yelton, R., Pajarillo, R., Patel, V., White, G., Ballard, H. J., Weber, E., Napier, E., Chong, E. R., Fraietta, J. A., Garfall, A. L., Porter, D. L., Milone, M. C., O'Connor, R., Schuster, S. J., Ruella, M., Blood Adv 8(3): 653-666, 2024
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies
Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox JJ, Scholler J, Marcellus B, Allman D, Fraietta JA, Samelson-Jones B, Milone MC, Monos D, Garfall AL, Naji A, Bhoj VG., Cell Rep Med 4(): 101336, 2023, PMID:38118406
F77 antigen is a promising target for adoptive T cell therapy of prostate cancer
Grover P, Nunez-Cruz S, Leferovich J, Wentz T, Bagchi A, Milone MC, Greene MI., Biochem Biophys Res Commun 680(): 51-60, 2023, PMID:37717341
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells
Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS., Nat Biotechnol 41(9): 1229-1238, 2023, PMID:36658341
CD38 as a pan-hematologic target for chimeric antigen receptor T cells
Glisovic-Aplenc, T., Diorio, C., Chukinas, J. A., Veliz, K., Shestova, O., Shen, F., Nunez-Cruz, S., Vincent, T. L., Miao, F., Milone, M. C., June, C. H., Teachey, D. T., Tasian, S. K., Aplenc, R., Gill, S., Blood Adv 7(16): 4418-4430, 2023
Association of Urine Fentanyl Concentration With Severity of Opioid Withdrawal Among Patients Presenting to the Emergency Department
Thakrar AP, Faude S, Perrone J, Milone MC, Lowenstein M, Snider CK, Spadaro A, Delgado MK, Nelson LS, Kilaru AS., J Addict Med 17(4): 447-453, 2023, PMID:36880886
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA., Blood Cancer Discov 4(): 118-133, 2023, PMID:36413381
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, Dhodapkar MV., Blood Cancer Discov., 2022
